Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics

Just months after Bristol Myers Squibb boarded Karuna Therapeutics for its much-hyped schizophrenia drug, the biotech’s leadership has set sail in a new venture.

Seaport Therapeutics is captained by CEO Daphne Zohar, a co-founder of Karuna, with Karuna’s former CEO Steven Paul, M.D., serving as the chair of Seaport’s board of directors. The biotech has been assembled by PureTech Health—where Zohar is also CEO—and supplied with $100 million for its mission to advance a pipeline of medicines targeting depression, anxiety and other neuropsychiatric disorders.